FDA
-
-
-
-
-
-
-
Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications
-
-
-
-
-
-
-
Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy
-
-
-
-
-
-
-
Edgewise Therapeutics to Present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle Society
-
-
-
-
-
-
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
-
-
-
-
-
-
-
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference
-
-
-
-
-
-
-
Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)
-
-
-
-
-
-
-
Edgewise Therapeutics (EWTX) Announces Positive Two-Year Topline Results from ARCH Open Label Trial of Sevasemten in Adults with Becker Muscular Dystrophy
-
323,752 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

